ABBV · 10-Q · 2026Q3 · Full report

Aesthetic Care Demand Trends

AbbVie Inc. · 2026-11-03 · Importance 42 · Surprise 40

Botox Cosmetic net revenues increased 4% in the third quarter and 8% in the first nine months, with growth driven primarily by increased consumer demand in certain international markets. Juvederm Collection declined 12% and 7%, respectively, as decreased consumer demand and unfavorable pricing weighed on performance. The filing also reports a decline in Other Aesthetics, with nine-month net revenues down 7% at constant currency.

Key facts

• In August 2026, the FDA accepted AbbVie’s supplemental BLA for Botox Cosmetic to improve the appearance of marked-to-very-marked masseter muscle prominence in adults for review. source
• In June 2026, the FDA approved Skinvive by Juvederm to reduce neck lines and improve neck appearance in adults over age 21. source
• In July 2026, the European Commission approved Boey (trenibotulinumtoxinE) for temporary improvement in the appearance of moderate-to-severe glabellar lines in adults. source
• Botox Cosmetic net revenues increased 4% in the three months and 8% in the nine months ended September 30, 2026, primarily due to increased consumer demand in certain international markets; nine-month revenues also benefited from U.S. customer-loyalty-program pricing changes in the prior year. source
• Juvederm Collection net revenues decreased 12% in the three months and 7% in the nine months ended September 30, 2026, primarily due to decreased consumer demand and unfavorable pricing. source